{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:28:44Z","timestamp":1784716124254,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T00:00:00Z","timestamp":1660435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000008","name":"Health Canada","doi-asserted-by":"publisher","award":["NCT03033732"],"award-info":[{"award-number":["NCT03033732"]}],"id":[{"id":"10.13039\/501100000008","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["SMN-139151"],"award-info":[{"award-number":["SMN-139151"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["SMN-139148"],"award-info":[{"award-number":["SMN-139148"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["SMN-139150"],"award-info":[{"award-number":["SMN-139150"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["SMN-139149"],"award-info":[{"award-number":["SMN-139149"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019211","name":"AbbVie Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005242","name":"Universit\u00e9 de Montr\u00e9al","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.drugalcdep.2022.109604","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T05:25:04Z","timestamp":1660713904000},"page":"109604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Buprenorphine\/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial"],"prefix":"10.1016","volume":"239","author":[{"given":"Christina","family":"McAnulty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Bastien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Eugenia Socias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bruneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Le Foll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Brissette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Ledjiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Marsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Jutras-Aswad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2022.109604_bib1","series-title":"Diagnostic and statistical manual of mental disorders: DSM-5","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.drugalcdep.2022.109604_bib2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/acps.13088","article-title":"Reduction in mortality risk with opioid agonist therapy: a systematic review and meta-analysis","volume":"140","author":"Bahji","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.drugalcdep.2022.109604_bib3","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/08897077.2021.2010251","article-title":"\u201cI wanted something that was more flexible\u201d: a qualitative study of patient preferences on choosing buprenorphine over methadone in a large, safety-net hospital opioid treatment program","volume":"43","author":"Checkley","year":"2022","journal-title":"Subst. Abus"},{"key":"10.1016\/j.drugalcdep.2022.109604_bib4","unstructured":"CRISM National Guideline Review Committee, 2018. CRISM National Guideline for the Clinical Management of Opioid Use Disorder."},{"key":"10.1016\/j.drugalcdep.2022.109604_bib5","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1038\/s41598-020-62556-0","article-title":"Metabolic and addiction indices in patients on opioid agonist medication-assisted treatment: a comparison of buprenorphine and methadone","volume":"10","author":"Elman","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drugalcdep.2022.109604_bib6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.drugalcdep.2018.04.024","article-title":"Crude estimates of prescription opioid-related misuse and use disorder populations towards informing intervention system need in Canada","volume":"189","author":"Fischer","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2022.109604_bib7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1037\/1064-1297.10.1.39","article-title":"Heroin craving and drug use in opioid-maintained volunteers: effects of methadone dose variations","volume":"10","author":"Greenwald","year":"2002","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2022.109604_bib8","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1176\/appi.ajp.2013.12060782","article-title":"DSM-5 criteria for substance use disorders: recommendations and rationale","volume":"170","author":"Hasin","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2022.109604_bib9","first-page":"21090964","article-title":"Flexible buprenorphine\/naloxone model of care for reducing opioid use in individuals with prescription-type opioid use disorder: an open-label, pragmatic, noninferiority randomized controlled trial","author":"Jutras-Aswad","year":"2022","journal-title":"Am. J. Psychiatry appiajp"},{"key":"10.1016\/j.drugalcdep.2022.109604_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.107639","article-title":"Craving and opioid use disorder: a scoping review","volume":"205","author":"Kleykamp","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2022.109604_bib11","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1177\/0269881117711710","article-title":"Buprenorphine\/naloxone versus methadone and lofexidine in community stabilisation and detoxification: a randomised controlled trial of low dose short-term opiate-dependent individuals","volume":"31","author":"Law","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2022.109604_bib12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/archpsyc.1996.01830050035005","article-title":"A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence","volume":"53","author":"Ling","year":"1996","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2022.109604_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cpr.2019.03.002","article-title":"Substance use and shame: a systematic and meta-analytic review","volume":"70","author":"Luoma","year":"2019","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.drugalcdep.2022.109604_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2019.05.034","article-title":"Stress and opioid use disorder: a systematic review","volume":"98","author":"MacLean","year":"2019","journal-title":"Addict. Behav."},{"key":"10.1016\/j.drugalcdep.2022.109604_bib15","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2022.109604_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.drugalcdep.2014.10.002","article-title":"Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients","volume":"145","author":"McHugh","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2022.109604_bib17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/ajad.12344","article-title":"Cue-induced craving to paraphernalia and drug images in opioid dependence","volume":"25","author":"McHugh","year":"2016","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2022.109604_bib18","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1037\/ccp0000399","article-title":"Effects of craving on opioid use are attenuated after pain coping counseling in adults with chronic pain and prescription opioid addiction","volume":"87","author":"Messina","year":"2019","journal-title":"J. Consult Clin. Psychol."},{"key":"10.1016\/j.drugalcdep.2022.109604_bib19","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/00003495-200969050-00006","article-title":"Buprenorphine\/naloxone: a review of its use in the treatment of opioid dependence","volume":"69","author":"Orman","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.drugalcdep.2022.109604_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0376-8716(00)80006-X","article-title":"Buprenorphine: a controlled clinical trial in the treatment of opioid dependence","volume":"60","author":"Pani","year":"2000","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2022.109604_bib21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0376-8716(00)00163-0","article-title":"Double-blind randomized trial of buprenorphine and methadone in opiate dependence","volume":"62","author":"Petitjean","year":"2001","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2022.109604_bib22","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1007\/s00213-018-4966-9","article-title":"Before and after: craving, mood, and background stress in the hours surrounding drug use and stressful events in patients with opioid-use disorder","volume":"235","author":"Preston","year":"2018","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.drugalcdep.2022.109604_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cct.2018.04.001","article-title":"The OPTIMA study, buprenorphine\/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale","volume":"69","author":"Socias","year":"2018","journal-title":"Conte Clin. Trials"},{"key":"10.1016\/j.drugalcdep.2022.109604_bib24","unstructured":"Somoza E., Dyrenforth S., Goldsmith J., Mezinskis J., Cohen M. In search of a universal drug craving scale. Paper presented at the Annual Meeting of the American Psychiatric Association, Miami Florida 1995."},{"key":"10.1016\/j.drugalcdep.2022.109604_bib25","series-title":"Surveillance of Opioid-and Stimulant-Related Harms in Canada","author":"Special Advisory Committee on the Epidemic of Opioid Overdoses","year":"2021"},{"key":"10.1016\/j.drugalcdep.2022.109604_bib26","unstructured":"World Drug Report 2020 (United Nations publication, Sales No. E.20.XI.6)."},{"key":"10.1016\/j.drugalcdep.2022.109604_bib27","unstructured":"World Drug Report 2021 (United Nations publication, Sales No. E.21.XI.8)."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871622003416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871622003416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:19:43Z","timestamp":1778631583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871622003416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":27,"alternative-id":["S0376871622003416"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109604","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Buprenorphine\/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109604","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109604"}}